Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

10.51 2.94

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.05

Max

10.68

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+188.93% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-221M 903M
Vorheriger Eröffnungskurs	7.57
Vorheriger Schlusskurs	10.51

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Okt. 2026, 23:56 UTC

Minerals Technologies Inc. traded roughly flat in after-market hours, following six consecutive sessions of declines and remaining significantly below its 20-day moving average.

9. Okt. 2026, 23:56 UTC

Correlated Moves

Proto Labs Inc's shares are roughly flat in after-market trading, while the AB Disruptors ETF sees slight gains from key holdings including Merck & Co and Spotify.

9. Okt. 2026, 23:56 UTC

Sensata Technologies Holding PLC shares are trading lower in after-market hours, maintaining a position around the middle of their one-month range.

9. Okt. 2026, 23:56 UTC

Wyndham Hotels & Resorts Inc is trading roughly flat in after-market hours, with a slight decline since Friday's close, remaining above its 20-day moving average.

9. Okt. 2026, 23:56 UTC

D.R. Horton Inc's shares declined in after-market trading, hitting their lowest cumulative return shortly after 6:00 PM, below the 20-day moving average.

9. Okt. 2026, 23:55 UTC

Preferred Bank shares are modestly lower in after-market trading, following a decline from an early peak and remaining below their 20-day moving average.

9. Okt. 2026, 23:55 UTC

American Homes 4 Rent is roughly flat in after-market trading, with a slight gain earlier in the session before settling back to current levels.

9. Okt. 2026, 23:55 UTC

Lear Corp shares are trading modestly lower in after-market hours, settling at the lowest point of the day, continuing a trend of four consecutive lower daily finishes.

9. Okt. 2026, 23:55 UTC

LyondellBasell Industries NV shares declined modestly during after-market trading on Friday, remaining near the lower end of their one-month trading range.

9. Okt. 2026, 23:55 UTC

Edgewell Personal Care Co is trading roughly flat in after-market hours, having slightly declined from an early peak while remaining above its 20-day moving average.

9. Okt. 2026, 23:55 UTC

Belden Inc is trading roughly flat in after-market hours, showing little change since Friday's close and positioned below its 20-day moving average.

9. Okt. 2026, 23:55 UTC

Avery Dennison Corp's shares remained roughly flat in after-market trading, positioned below its 20-day moving average and near the lower end of its one-month range.

9. Okt. 2026, 23:55 UTC

Verra Mobility Corp shares advanced in after-market trading.

9. Okt. 2026, 23:55 UTC

Miller Industries Inc is trading modestly higher in after-market hours, with a cumulative return of 0.59% since the market reopened.

9. Okt. 2026, 23:55 UTC

Casella Waste Systems Inc shares are trading higher in after-market hours, maintaining a slight gain since Friday's close amid mixed economic data.

9. Okt. 2026, 23:55 UTC

Chemours Co shares are trading modestly higher in after-market hours.

9. Okt. 2026, 23:55 UTC

Black Hills Corp shares traded modestly lower in after-market hours on Friday, following a notable decline shortly after the market reopened.

9. Okt. 2026, 23:55 UTC

Johnson Outdoors Inc shares declined modestly in after-market trading, with a cumulative return of around -0.30% since Friday's close, near a one-month low.

9. Okt. 2026, 23:55 UTC

Event

PNC Financial Services Group is set to report Q3 FY2026 earnings on October 15, with expected EPS of $4.91 and revenue forecast of $6.6 billion.

9. Okt. 2026, 23:55 UTC

AutoNation Inc's shares are roughly flat in after-market trading, remaining near the lower end of their one-month range amid a challenging performance backdrop.

9. Okt. 2026, 23:55 UTC

Wix.Com Ltd has seen a slight increase in after-market trading, continuing a stable trend following three consecutive sessions of higher finishes.

9. Okt. 2026, 23:55 UTC

In after-market trading, Arrow Electronics Inc has remained roughly flat, fluctuating around the middle of its one-month range since Friday's close.

9. Okt. 2026, 23:55 UTC

CBRE Group Inc is trading roughly flat during after-market hours, with a slight decline from earlier levels and positioned below its 20-day moving average.

9. Okt. 2026, 23:51 UTC

RPM International Inc shares declined modestly during after-market hours, retracing to their lowest level of the session amid unusual weakness in broader market performance.

9. Okt. 2026, 23:51 UTC

Barrick Mining Corp shares traded modestly lower during after-market hours on Friday, continuing a steady decline and remaining below their 20-day moving average.

9. Okt. 2026, 23:51 UTC

Paccar Inc's shares declined in after-market trading, moving lower since Friday's close and currently positioned below its 20-day moving average.

9. Okt. 2026, 23:51 UTC

Kraft Heinz Co shares advanced modestly during after-market hours, reaching a high return since Friday's close despite earlier session weakness.

9. Okt. 2026, 23:51 UTC

Agree Realty Corp shares declined modestly in after-market trading, retracing from a brief peak and remaining below their 20-day moving average.

9. Okt. 2026, 23:51 UTC

Boyd Gaming Corp's shares advanced in after-market trading, following a modest increase since Friday's close, despite earlier pulling back from a session high.

9. Okt. 2026, 23:51 UTC

Correlated Moves

Blue Owl Capital Inc is trading higher in after-market hours, reflecting a continued upward trend following gains in Ares Capital Corp.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

188.93% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD 188.93%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.